Keyword,Priority
(R)-9bMS,High
[225Ac]Ac-FL-020,High
[225Ac]-AZD2284,High
[255Ac]Ac-PSMA-R2,High
177Lu-PSMA-I&T,High
177Lu-rhPSMA-10.1,High
177Lu-TLX591,High
225Ac-J591,High
225Ac-pelgifatamab (BAY3546828),High
225Ac-PSMA-617,High
225Ac-PSMA-Trillium (BAY3563254),High
225Ac-TLX592,High
64Cu-SAR-BBN,High
64Cu-SAR-bisPSMA,High
67CU SAR-BBN,High
67Cu-SAR-bisPSMA,High
68Ga-OncoACP3,High
ABBV-969,High
ACE-232,High
AcTFirst,High
ADC,High
ADRX-0405,High
ALPHABREAK,High
androgen deprivation therapy,High
androgen receptor degraders,High
AR PROTAC,High
ARANOTE,High
ARASEC,High
ARASTEP,High
ARC-706,High
ARPI (androgen receptor pathway inhibitors),High
ART-101,High
ASP5541,High
AZD0754,High
BAY2315497,High
BMS-986365,High
BMS-986460,High
BNT324/DB-1311,High
Cabozantinib,High
CAN-2409,High
CAPitello-280,High
Capitello-281,High
CD28,High
CD3,High
CONTACT-02,High
CONV01-α,High
CONVERGE-01,High
DASL-HiCaP,High
ECLIPSE,High
EMBARK,High
ENZARAD,High
EvoPAR-PRO1,High
EZH2,High
FOR46,High
FPI-2265,High
Ga-68-NGUL,High
GDC-2992 / RO7656594,High
GSK5458514,High
Ideate-Prostate01,High
Ifinatamab deruxtecan,High
infinatamab deruxtecan (I-Dxd),High
INKmune,High
JANX007,High
KLK2,High
Lorigerlimab,High
Lu-177-DGUL,High
Ludotadipep (177Lu-FC705),High
MEVPRO-1,High
MEVPRO-2,High
MEVPRO-3,High
Mevrometostat,High
Novel,High
Nubeqa (darolutamide),High
OMAHA1,High
OMAHA2,High
ONC-392,High
opevesostat,High
ORIC-944,High
PARP,High
PARP inhibitor,High
Pluvicto (Lu-PSMA-617),High
PRC2,High
PROpel,High
ProstACT,High
PrTK03,High
PSMA,High
PSMAcTION,High
PSMA-DC,High
PSMAddition,High
PSMAdittion,High
PSMAfore,High
PSMAndARPI,High
PT-112,High
Radioligands (RLT),High
rechARge,High
REGN4336,High
REGN5678,High
REGN7075,High
Rubraca (rucaparib),High
Saruparib (AZD-5305),High
SatisfACtion,High
SPLASH,High
STEAP1,High
STEAP2,High
SV-102,High
SX-682,High
TALAPRO-2,High
TALAPRO-3,High
Talzenna (talazoparib),High
TRITON-3,High
VIR-5500,High
Vobramitamab duocarmazine,High
Vudalimab,High
Xaluritamig (AMG509),High
XALute,High
Xtandi (enzalutamide),High
